MedTrace Logo

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

NCT03168061 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-02-28

No results posted yet for this study

Summary

The goal of this study is to find the highest tolerated dose of NC-6300 that can be given to patients with advanced solid tumors or soft tissue sarcoma. The safety and tolerability of the drug will also be studied.

Conditions

  • Solid Tumor
  • Soft Tissue Sarcoma
  • Metastatic Sarcoma
  • Sarcoma

Interventions

DRUG

NC 6300

Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose

Sponsors & Collaborators

  • NanoCarrier Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Atsushi Osada · NanoCarrier Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2020-07-31
Completion
2020-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03168061 on ClinicalTrials.gov